A Phase ll trial to measure the response rate (Rate of recurrence following treatment) ,toxicity and safety of weekly intravesical gemcitabine in patients with transitional cell carcinoma of the bladder.
Phase of Trial: Phase II
Latest Information Update: 22 Jun 2016
At a glance
- Drugs Gemcitabine (Primary)
- Indications Bladder cancer
- Focus Therapeutic Use
- 08 Jun 2016 Status changed from recruiting to completed.
- 30 Aug 2011 New trial record